Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.

2 Paediatric Intensive Care Unit ... paper has highlighted the differences in the respiratory management offered to infants with type 1 spinal muscular atrophy (SMA-1).1 Current views appear polarised ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...

They now expect apitegromab to reach over $2 billion in global revenue ... strong growth potential for apitegromab in spinal muscular atrophy. The company could enter the commercial stage by ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken 14 days apart can deliver significant clinical benefits in patients with ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

McClurken-Gibney was diagnosed with spinal muscular atrophy, a rare, inherited neuromuscular disorder that causes muscle weakness and wasting due to nerve cell dysfunction. Before his death at the ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...